NanoVirides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company's proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The approval represents a significant milestone for the company, as NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses. According to NanoVirides, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing.
The company outlined the next steps, which include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. NanoVirides noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale.
This development comes amid an ongoing outbreak of Bundibugyo ebolavirus in the DRC, highlighting the need for effective and easily deployable treatments. The oral gummy formulation could potentially simplify administration and improve patient compliance compared to traditional intravenous therapies. For more details, the full press release is available at https://nnw.fm/1ewVT.
NanoVirides is a clinical-stage company specializing in nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for a range of viral infections, including RSV, COVID, Long COVID, influenza, mpox, and Ebola. The company also has other candidates in development, such as NV-HHV-1 for shingles. However, the company cautions that drug development is lengthy and requires substantial capital, with no assurance of successful clinical trials or final products.
The company's technology is based on the TheraCour nanomedicine platform, licensed from TheraCour Pharma. NanoVirides holds exclusive licenses for several human viral diseases, including HIV, Hepatitis B and C, rabies, herpes, influenza, dengue, and Ebola. The company's business model relies on licensing technology for specific applications.
Investors can find the latest news and updates regarding NNVC at the company's newsroom: https://nnw.fm/NNVC. This announcement underscores the potential for oral antiviral treatments in outbreak settings, but as with all drug development, outcomes remain uncertain.
